Co-Diagnostics to showcase PCR diagnostics at WHX Kuala Lumpur.

Co-Diagnostics will be hosting a booth at WHX Kuala Lumpur from July 16-18, 2025. The company aims to promote its PCR in vitro diagnostics for infectious diseases, Co-Primers technology and applications, and introduce its upcoming Co-Dx PCR platform. The event is expected to attract over 10,000 visitors from 54 countries.

Co-Diagnostics (NASDAQ:CODX) has announced its participation at the World Healthcare Expo (WHX) Kuala Lumpur, scheduled to take place from July 16-18, 2025, at MITEC. The company will use this platform to promote its PCR in vitro diagnostics for infectious diseases, specifically its Co-Primers technology and applications. Additionally, Co-Diagnostics will introduce its upcoming Co-Dx PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test, both of which are slated for clinical evaluations later this year.

The event, which is expected to attract over 10,000 visitors from 54 countries, will serve as an opportunity for Co-Diagnostics to showcase its technological advancements in the field of PCR diagnostics. The company's participation is partially supported by a grant from World Trade Center Utah.

In a recent study published in MDPI [1], Co-Diagnostics' DRDP buffer was evaluated for its compatibility with direct PCR diagnostics. The study focused on DNA viruses (HSV-1, HSV-2, VZV) and demonstrated that DRDP buffer effectively lyses virions and preserves DNA/RNA without the need for nucleic acid extraction. This capability aligns with the broader need for point-of-care outbreak diagnostics, providing enhanced biosafety and timely results.

Co-Diagnostics' booth at WHX Kuala Lumpur will highlight the company's commitment to innovation in the field of diagnostic technologies. The event will offer attendees the chance to learn more about the company's advanced PCR diagnostics and the potential of its Co-Dx PCR platform in addressing emerging infectious diseases.

References:
[1] https://www.mdpi.com/2813-9038/2/3/12